King's College London

Research portal

Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.

Research output: Contribution to journalArticlepeer-review

Robin Fackrell, Camille Carroll, Donald Grosset, Biju Mohamed, Papari Prashanth Reddy, Miriam Parry, Kallol Ray Chaudhuri, Thomas Foltynie

Original languageEnglish
Pages (from-to)349-360
JournalNeurodegenerative Disease Management in Future Medicine
Published8 Oct 2018


  • nmt-2018-0020_28Jun18

    nmt_2018_0020_28Jun18.pdf, 504 KB, application/pdf

    Uploaded date:19 Feb 2019

    Version:Accepted author manuscript

King's Authors


In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454